HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Pan-Sarbecovirus Neutralizing Antibodies in BNT162b2-Immunized SARS-CoV-1 Survivors.

Abstract
Emerging severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern pose a challenge to the effectiveness of current vaccines. A vaccine that could prevent infection caused by known and future variants of concern as well as infection with pre-emergent sarbecoviruses (i.e., those with potential to cause disease in humans in the future) would be ideal. Here we provide data showing that potent cross-clade pan-sarbecovirus neutralizing antibodies are induced in survivors of severe acute respiratory syndrome coronavirus 1 (SARS-CoV-1) infection who have been immunized with the BNT162b2 messenger RNA (mRNA) vaccine. The antibodies are high-level and broad-spectrum, capable of neutralizing not only known variants of concern but also sarbecoviruses that have been identified in bats and pangolins and that have the potential to cause human infection. These findings show the feasibility of a pan-sarbecovirus vaccine strategy. (Funded by the Singapore National Research Foundation and National Medical Research Council.).
AuthorsChee-Wah Tan, Wan-Ni Chia, Barnaby E Young, Feng Zhu, Beng-Lee Lim, Wan-Rong Sia, Tun-Linn Thein, Mark I-C Chen, Yee-Sin Leo, David C Lye, Lin-Fa Wang
JournalThe New England journal of medicine (N Engl J Med) Vol. 385 Issue 15 Pg. 1401-1406 (10 07 2021) ISSN: 1533-4406 [Electronic] United States
PMID34407341 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2021 Massachusetts Medical Society.
Chemical References
  • Antibodies, Viral
  • Broadly Neutralizing Antibodies
  • COVID-19 Vaccines
  • BNT162 Vaccine
Topics
  • Antibodies, Viral (blood)
  • B-Lymphocytes
  • BNT162 Vaccine
  • Broadly Neutralizing Antibodies (blood)
  • COVID-19 (immunology)
  • COVID-19 Vaccines (immunology)
  • Humans
  • Immunogenicity, Vaccine
  • Phylogeny
  • Severe acute respiratory syndrome-related coronavirus (genetics, immunology)
  • SARS-CoV-2 (genetics, immunology)
  • Severe Acute Respiratory Syndrome (immunology)
  • Survivors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: